Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease

This study has been completed.
Sponsor:
Information provided by:
University of Alberta
ClinicalTrials.gov Identifier:
NCT01215890
First received: October 5, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted

October 5, 2010
October 5, 2010
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease
A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients

The occurrence of bone loss in Crohn's disease patients is an important clinical problem for both patients with and without active disease. While therapy does exist for treatment and prevention of low BMD, evidence of its efficacy in Crohn's disease patients is lacking. The current standard of therapy in Canada for the treatment of osteoporosis is etidronate, with adequate calcium and vitamin D supplementation.

The primary objective of the study is to assess the efficacy of risedronate, compared to placebo, administered once-weekly, in the treatment of low BMD of the spine and hip in patients with Crohn's disease at 12 months, based on an intention-to-treat analysis.

Not Provided
Interventional
Phase 4
Not Provided
  • Crohn's Disease
  • Low Bone Mineral Density
  • Drug: risedronate
  • Drug: placebo
  • Active Comparator: risedronate plus calcium and viamin D
    Intervention: Drug: risedronate
  • Placebo Comparator: placebo plus clacium and vitamin D
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Subjects who are 18 years of age, or older.
  • Crohn's disease, as documented by clinical, radiologic, endoscopic or histologic examination.
  • Osteoporosis (T score less than -2.5) or osteopenia (T score between -1.0 and -2.5), as determined by dual energy X-ray absorptiometry.

Exclusion Criteria:

  • Known bone disorders other than osteoporosis (such as hyperparathyroidism, Paget's disease, renal osteodystrophy and documented osteomalacia)
  • Abnormal thyroid function. Those patients on thyroxine replacement must not have had a change in dose in the two months prior to prospective data collection program entry
  • Clinically significant renal impairment (serum creatinine ≥ 2x normal).
  • Clinical Short Bowel Syndrome
  • Patients on total parenteral or enteral nutrition
  • Spinal anatomy that would not allow adequate assessment of lateral spine using DEXA
  • Patients who had received:

    1. previous bisphosphonate therapy
    2. fluoride supplement in the 24 months prior to entry
    3. calcium supplements of more than 1.0g/day in the 6 months prior to entry
    4. vitamin D supplements greater than 1000 IU/day in the 6 months prior to entry
    5. calcitonin in the 3 months prior to entry
  • Females on hormone replacement therapy who do not agree to continue the therapy for the duration of the prospective data collection program
  • Men on testosterone who do not agree to continue it for the duration of the prospective data collection program
  • Pregnancy or women who are breastfeeding
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01215890
RIS-RF
Not Provided
Not Provided
University of Alberta
Not Provided
Principal Investigator: Richard Fedorak, MD University of Alberta
University of Alberta
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP